European Commission (EC) Approves Gilead Sciences, Inc.'s Vitekta, To Treat HIV-1 Infection

European Commission Approves Gilead's VitektaTM, an Integrase Inhibitor for the Treatment of HIV-1 Infection FOSTER CITY, Calif.-- -- Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for VitektaTM tablets, an integrase inhibitor for the treatment of HIV-1 infection in adults without known ... (more)

http://www.biospace.com/news_story.aspx?StoryID=316028&full=1